PLC's Heart Laser Takes Over Center Stage
Executive SummaryVenture capitalists and big device companies have lamented for years that laser medicine was the black hole of medical device investment. Though the consumer-oriented laser devices have met with modest commercial success, most laser systems have been only marginally effective in the clinic, falling far short of the expected payoff given the investment.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.